BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

889 related articles for article (PubMed ID: 30170567)

  • 1. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.
    MacDonald TM; Tran C; Kaitu'u-Lino TJ; Brennecke SP; Hiscock RJ; Hui L; Dane KM; Middleton AL; Cannon P; Walker SP; Tong S
    BMC Pregnancy Childbirth; 2018 Aug; 18(1):354. PubMed ID: 30170567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age.
    Garcia-Manau P; Mendoza M; Bonacina E; Garrido-Gimenez C; Fernandez-Oliva A; Zanini J; Catalan M; Tur H; Serrano B; Carreras E
    Acta Obstet Gynecol Scand; 2021 Jan; 100(1):119-128. PubMed ID: 32860218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.
    Rizos D; Eleftheriades M; Karampas G; Rizou M; Haliassos A; Hassiakos D; Vitoratos N
    Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):225-30. PubMed ID: 24035323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks.
    Fadigas C; Peeva G; Mendez O; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Aug; 46(2):191-7. PubMed ID: 25825848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30-34 weeks.
    Bakalis S; Peeva G; Gonzalez R; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Oct; 46(4):446-51. PubMed ID: 25826154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35-37 weeks' gestation.
    Ciobanu A; Rouvali A; Syngelaki A; Akolekar R; Nicolaides KH
    Am J Obstet Gynecol; 2019 May; 220(5):486.e1-486.e11. PubMed ID: 30707967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of impaired placentation at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
    Ciobanou A; Jabak S; De Castro H; Frei L; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2019 Jul; 54(1):79-86. PubMed ID: 31100188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
    Valiño N; Giunta G; Gallo DM; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Feb; 47(2):194-202. PubMed ID: 26094952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction.
    Vatten LJ; Åsvold BO; Eskild A
    Acta Obstet Gynecol Scand; 2012 Dec; 91(12):1388-94. PubMed ID: 22882089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal serum biomarkers of placental insufficiency at 24-28 weeks of pregnancy in relation to the risk of delivering small-for-gestational-age infant in Sylhet, Bangladesh: a prospective cohort study.
    Rahman S; Islam MS; Roy AK; Hasan T; Chowdhury NH; Ahmed S; Raqib R; Baqui AH; Khanam R
    BMC Pregnancy Childbirth; 2024 Jun; 24(1):418. PubMed ID: 38858611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of small-for-gestational-age neonates: screening by maternal biochemical markers at 30-34 weeks.
    Bakalis S; Gallo DM; Mendez O; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Aug; 46(2):208-15. PubMed ID: 25826797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum placental growth factor and soluble fms-like tyrosine kinase 1 at mid-gestation in healthy women: Association with small-for-gestational-age neonates.
    Furuta I; Umazume T; Kojima T; Chiba K; Nakagawa K; Hosokawa A; Ishikawa S; Yamada T; Morikawa M; Minakami H
    J Obstet Gynaecol Res; 2017 Jul; 43(7):1152-1158. PubMed ID: 28422347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of second trimester maternal serum sFlt-1, PlGF and their ratio in the prediction of preeclampsia].
    Gao J; Shen J; Jiang Y; Zhou X; Qi H; Liu X; Liu J; Yang J; Bian X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jan; 49(1):22-5. PubMed ID: 24694913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.
    Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B
    Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
    Dragan I; Wright D; Fiolna M; Leipold G; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Feb; 49(2):209-212. PubMed ID: 27671743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor.
    Shibata E; Rajakumar A; Powers RW; Larkin RW; Gilmour C; Bodnar LM; Crombleholme WR; Ness RB; Roberts JM; Hubel CA
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4895-903. PubMed ID: 15886253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of competing-risks model with angiogenic factors in midgestation screening for preterm growth-related neonatal morbidity.
    Papastefanou I; Menenez M; Szczepkowska A; Gungil B; Syngelaki A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2024 May; 63(5):613-618. PubMed ID: 38057964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.
    Chaiworapongsa T; Romero R; Korzeniewski SJ; Kusanovic JP; Soto E; Lam J; Dong Z; Than NG; Yeo L; Hernandez-Andrade E; Conde-Agudelo A; Hassan SS
    Am J Obstet Gynecol; 2013 Apr; 208(4):287.e1-287.e15. PubMed ID: 23333542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women.
    Forest JC; Thériault S; Massé J; Bujold E; Giguère Y
    Clin Chem Lab Med; 2014 Aug; 52(8):1169-78. PubMed ID: 24535301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.